ReviewFrontiers in oncology2025
Progress of arylacetamide deacetylase research in metabolic diseases.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Late-Stage Functionalization of the Rifamycin Core via Click Chemistry Toward New Antibacterial Derivatives.Molecules (Basel, Switzerland) · 2026Article
- Mechanism-based new approach methodologies for in vitro detection of chemical-induced liver steatosis.Archives of toxicology · 2026Review
- First functional and taxonomic insights into the microbiome of edible snail, Cipangopaludina lecythis via shotgun metagenomics.Antonie van Leeuwenhoek · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arylacetamide deacetylase (AADAC), a microsomal serine esterase belonging to the polygenic hydrolase family, is predominantly localized in the liver and intestine. It plays a significant role in drug metabolism, lipid metabolism, and the pathogenesis of various diseases. In the context of drug metabolism, AADAC is vital for ensuring the safety of ester-based drugs. Its substrate specificity for short-chain acyl groups, along with genetic polymorphisms among individuals and species, influences drug-related processes. Regarding lipid metabolism, The lipase activity of AADAC is involved in the hydrolysis of cholesterol and triglycerides, lipid mobilization, and the assembly of lipoproteins. The expression of AADAC is regulated by multiple factors. It is associated with metabolic disorders; for instance, its decreased expression in the liver during obesity may impact triglyceride metabolism, and it may also have an indirect role in diabetes. In cardiovascular diseases, AADAC holds potential as a diagnostic marker. Its role in cancer is heterogeneous, being downregulated in certain cancers while upregulated in others, such as pancreatic and ovarian cancers, where it acts to inhibit cancer progression. Within the nervous system, AADAC may influence neurotransmitter regulation and drug metabolism. Currently, research on AADAC agonists is limited, and the development of inhibitors presents challenges, underscoring the necessity for further investigation in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.